This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
GNT Pharma Co., Ltd.
Drug Names(s): AAD-2004
Description: AAD-2004 was developed as a dual function drug to remove excess free radicals and PGE2, the key mediators of nerve injury in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). AAD-2004 is a potent microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor and spin trapping molecule. Anti-symptomatic and disease-modifying potential of AAD-2004 has been verified in animal models of AD, ALS, and PD. AAD-2004 also shows anti-depression effects comparable to fluoxetine.
Deal Structure: In April 2012, Global Neurotech (GNT) Pharma announced a strategic relationship with Toyota Tsusho Corporation (TTC) . TTC will represent GNT Pharma exclusively in Japan in promoting its products and technologies in the area for neurological and inflammatory diseases.
Scrip Alexar Therapeutics Inc.
Additional information available to subscribers only: